Table 3.

Linear mixed effects models of repeated measures of biomarkers on development of new functional impairment.

	B	95% CI	p-value
Neuron Specific Enolase Model
Intercept	2.566	(1.992, 3.140)	<.001
Neuron specific enolase	0.000	(0.000, 0.001)	.270
Time	0.064	(−0.015, 0.143)	.111
Illness severity	0.120	(0.089, 0.151)	<.001
S100b Model
Intercept	2.555	(1.979, 3.131)	<.001
s100b	0.002	(−0.009, 0.014)	.699
Time	0.064	(−0.016, 0.144)	.114
Illness severity	0.117	(0.084, 0.151)	<.001
C-Reactive Protein Model
Intercept	2.552	(1.979, 3.125)	<.001
C-reactive protein	0.000	(0.000, 0.000)	.182
Time	0.081	(0.000, 0.165)	.057
Illness severity	0.114	(0.082, 0.146)	<.001
Interleukin-6 Model
Intercept	2.559	(1.983, 3.135)	<.001
Interleukin-6	0.000	(0.000, 0.000)	.857
Time	0.062	(−0.018, 0.142)	.120
Illness severity	0.120	(0.087, 0.154)	<.001
Vascular Endothelial Growth Factor
Intercept	2.562	(2.002, 3.122)	<.001
Vascular Endothelial Growth Factor	−0.001	(−0.002, 0.000)	.003
Time	0.081	(0.003, 0.169)	.043
Illness severity	.120	(0.089, 0.150)	<.001
Brain-Derived Neurotrophic Factor Model
Intercept	2.550	(1.993, 3.106)	<.001
Brain-derived neurotrophic factor	−0.001	(−0.002, −0.001)	.001
Time	0.096	(0.017, 0.175)	.018
Illness severity	0.106	(0.075, 0.138)	<.001